Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: AT1 blocker candesartan|DRUG: Placebo
Sponsor: The Netherlands Cancer Institute
Collaborators: AstraZeneca|Roche Pharma AG